

Blue Cross Blue Shield of Massachusetts is an Independent Licenses of the Blue Cross and Blue Shield Association

Request for Clinical Exception to BCBSMA Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy (SBRT) Policy

Before Rendering Services	After Delivery of Services
Services rendered both in and outside of	Services rendered in Massachusetts:
Massachusetts:	Mail to: Blue Cross Blue Shield of Massachusetts
Blue Cross Blue Shield of Massachusetts	PO Box 986065
Case Creation/Medical Policy	Boston, MA 02298
Fax to: 1-888-282-0780	Services rendered outside of Massachusetts:
	Submit to your Local Plan

Complete the Clinical Exception Form for BCBSMA Medical Policy 277, SBRT

Providers **must** complete the Clinical Exception and Notification Form below when requesting coverage:

 For not medically necessary and investigational indications, described in the medical policy 277, SBRT. See <u>exception section</u> of the form.

If yes, provide the clinical trial number:			
rmation	-	Provider/Facility Information	
		Provider	
		Name:	
		Provider NPI:	
		Facility Name:	
		Facility NPI:	
From:	То:	Contact	
		Name:	
	(Up to 5 maximum)	Contact Phone:	
	rmation	rmation From: To:	

EXCEPTION—Organ-confined Prostate Cancer

Is the member enrolled in a clinical trial?

Yes

No

In consultation with practicing radiation oncologists, the following clinical exception was established based on acceptable radiation dosage and volume limits to adjacent organs when treating organ-confined prostate cancer. This is a supplement to our coverage statements regarding the use of SBRT to treat this condition. SBRT for organ-confined prostate cancer will be covered by exception for patients with tumors considered to be at low or intermediate risk. Please indicate below that the patient meets all the criteria for either low risk or intermediate risk by checking the appropriate criteria in the table below.

Risk Level	Criteria for Exception – patient must meet all criteria below
Low Risk	☐ Prostate volume less than 100 cc and

	☐ Tumor stage T1c – T2a and
	☐ Gleason score <=6 and PSA<= 10
Intermediate Risk	☐ Prostate volume <100cc and
	☐ Tumor stage T1c-T2c and
	☐ Gleason score <= 6 and PSA 10-20
	Or
	☐ Gleason score 7 and PSA <10